Literature DB >> 31820411

Assessing the downstream value of first-line cardiac positron emission tomography (PET) imaging using real world Medicare fee-for-service claims data.

Qinli Ma1, Gayathri Sridhar2, Thomas Power3, Abiy Agiro2.   

Abstract

BACKGROUND: Higher imaging quality makes cardiac positron emission tomography (PET) desirable for evaluation of suspected coronary artery disease (CAD). High cost of PET imaging may be offset by reduced utilization and/or improved outcomes.
METHODS: This retrospective observational study utilized Medicare fee-for-service dataset. Study participants had no CAD diagnosis within 1 year prior to initial imaging. The PET group (PET imaging) and propensity score matched comparison group (single photon emission computed tomography or stress echocardiography) underwent index imaging between January 2014 and December 2016. Outcomes were analyzed using generalized linear models.
RESULTS: Among 144,503 study subjects, 4619 (3.2%) had PET and 139,884 (96.8%) had conventional imaging. After matching, each group had 4619 patients (mean age 74 years, 59% female). The PET group had lower radiation exposure (3.8 milliSievert less per year, 95% CI - 3.96 to - 3.64, P < .0001) and unstable coronary syndrome (incidence rate ratio (IRR) 0.77, 95% CI 0.64-0.94, P = .008). The PET group experienced more hospital admissions (IRR 1.10, 95% CI 1.06-1.15, P < .0001), more use of percutaneous coronary intervention (IRR 1.24, 95% CI 1.02-1.50, P = 0.03), while similar mortality rate (hazard ratio 0.95, 95% CI 0.78-1.14, P = 0.55). The PET group had higher medical spending ($2358.2 vs $1774.3, difference = $583.9 per patient per month, P < .0001).
CONCLUSIONS: First-line PET imaging was not associated with reduced levels of utilization and spending. Clinical outcomes were mostly similar.
© 2019. American Society of Nuclear Cardiology.

Entities:  

Keywords:  CAD; PET; SPECT; diagnostic and prognostic application; echo; vascular imaging

Mesh:

Year:  2019        PMID: 31820411     DOI: 10.1007/s12350-019-01974-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  2 in total

1.  The quest to improve sudden cardiac death prediction using sympathetic innervation scintigraphy: Chasing a mirage?

Authors:  Firas J Al Badarin; Poghni Peri-Okonny
Journal:  J Nucl Cardiol       Date:  2019-05-20       Impact factor: 5.952

2.  Economic analysis of clinical positron emission tomography of the heart with rubidium-82.

Authors:  K L Gould; R A Goldstein; N A Mullani
Journal:  J Nucl Med       Date:  1989-05       Impact factor: 10.057

  2 in total
  4 in total

1.  The complicated business of testing our diagnostic tests!

Authors:  Prem Soman; Syed Bukhari
Journal:  J Nucl Cardiol       Date:  2020-01-29       Impact factor: 5.952

2.  Reduced acquisition times for measurement of myocardial blood flow with 99mTc-tetrofosmin and solid-state detector SPECT.

Authors:  Jeffrey Do; Terrence D Ruddy; R Glenn Wells
Journal:  J Nucl Cardiol       Date:  2020-02-05       Impact factor: 5.952

3.  A method to measure the extent of myocardial ischemia and steal with SPECT myocardial blood flow quantitation.

Authors:  Lung-Ching Chen; Huei-Fong Hung; Bor-Hsin Jong; Sheng-Che Lin; Chia-Lu Yeh; Chi-Tai Ku; Yen-Kung Chen; Bailing Hsu
Journal:  Ann Nucl Med       Date:  2020-06-30       Impact factor: 2.668

4.  Quantification of myocardial blood flow by CZT-SPECT with motion correction and comparison with 15O-water PET.

Authors:  Yuka Otaki; Osamu Manabe; Robert J H Miller; Alain Manrique; Catherine Nganoa; Nathaniel Roth; Daniel S Berman; Guido Germano; Piotr J Slomka; Denis Agostini
Journal:  J Nucl Cardiol       Date:  2019-08-26       Impact factor: 3.872

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.